drugset / Trial / NCT00826241
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
Phase 2
Completed
58 enrolled
National Institutes of Health Clinical Center (CC)
CERN Foundation - Collaborative Ependymoma Research Network · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
Timeline
- Start
- 2009-01
- Primary completion
- 2018-07-31
- Completion
- 2018-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 1250 mg | Oral |
| Subject | Temozolomide | Small molecule | 125 mg/m2 | Oral |